We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Tucatinib Against Stage IV HER2+ Breast Cancer, Phase III Trial Results Promising

News   Dec 12, 2019 | Original story from University of Colorado Cancer Center

 
Tucatinib Against Stage IV HER2+ Breast Cancer,  Phase III Trial Results Promising
 
 
 

RELATED ARTICLES

Gene Therapy for Duchenne Muscular Dystrophy Successful in Pigs

News

An interdisciplinary Munich research team led by scientists from TUM has for the first time succeeded in correcting the mutated dystrophin gene in living pigs. In order to cut the defective gene sequence from the DNA of the animals' muscle and heart cells, the researchers modified the Crispr-Cas9 gene scissors.

READ MORE

Metabolic Vulnerability Could Inspire New Pancreatic Cancer Treatments

News

Researchers have identified a new vulnerability in pancreatic cancer, which may provide a potential strategy for combating one of the most treatment-resistant malignancies.

READ MORE

Human Body-on-Chip Systems Boost Drug Testing Capabilities

News

A team of researchers has designed a comprehensive multi-organ-on-a-chip platform that supports effective in vitro-to-in vivo translation of human drug pharmacology.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE